Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

NCT07363512 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER_GOV

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT: Radiotherapy combined with tislelizumab and anlotinib

Sponsor

Henan Cancer Hospital